EVE Health Group Submits First Commercial Order For Dyspro Dysmenorrhoea Treatment

EVE Health Group (ASX: EVE) has submitted the first commercial purchase order for its proprietary gummy-format pharmaceutical product Dyspro to support women experiencing dysmenorrhoea (painful menstruation) and related health concerns.

Dyspro is a pharmaceutical-grade formulation containing a validated blend of cannabinoid-derived active ingredients and is EVE’s first internally-developed product to progress from formulation to scaled manufacturing.

The order comes hot on the heels of the company’s recent Nextract acquisition and expansion into prescription pharmaceutical products.

‘Readiness to Deliver’

EVE executive director and chief scientific officer Dr Stuart Gunzburg said the commercial order represented a significant milestone for the company.

“Submitting this first Dyspro order signals our readiness to deliver on the next phase of our growth strategy,” he said.

“We are proud to see our internal formulation efforts translating into a tangible product that will soon be available to support women’s health through regulated prescription channels.”

Prescriber Network

EVE Health will supply the new order with product it has manufactured at a GMP-certified Australian facility and expects to commence distribution within five weeks.

The company is currently assessing national distribution options through proven pharmaceutical logistics partners, with the successful parties needing to ensure timely access, compliance with all regulatory handling requirements and scalable infrastructure to support Dyspro’s growth in demand.

Dyspro is already available in Australia to a network of authorised prescribers and no further regulatory steps are required to enable commercial supply.

Prevalent Condition

Dysmenorrhoea is a prevalent condition among Australian women of reproductive age, with symptoms that can significantly impact daily activities and result in absence from work or study.

The economic implications are also substantial, with the estimated annual burden of menstrual symptoms in Australia at approximately $14.2 billion, primarily due to lost productivity.

In more severe cases, dysmenorrhoea may be associated with endometriosis, which is a chronic inflammatory condition estimated to affect up to 10% of Australian women.

Treatment Markets

The global dysmenorrhoea treatment market reached US$10.9b in 2024 across the top seven pharmaceutical markets of the US, UK, European Union, and Japan.

Analysts forecast the market will double in value by 2035 at a compound annual growth rate (CAGR) of 5.73%.

The Australian endometriosis treatment market — which is often co-morbid with dysmenorrhoea — is projected to reach US$76.4 million by 2030, growing at a CAGR of 13% from 2025.